Rocket Pharmaceuticals Hit with Class Action Lawsuit Over Death of Patient in Gene Therapy Trial

Pomerantz Law Firm has filed a class action lawsuit against Rocket Pharmaceuticals, alleging securities fraud and unlawful business practices. The lawsuit concerns the company's investigational gene therapy for Danon disease, which experienced an unexpected serious adverse event and led to a 62.84% decline in stock price. Investors who purchased or acquired Rocket securities during the class period have until August 11, 2025, to ask the Court to appoint them as Lead Plaintiff.

NEW YORK, July 2, 2025 — Pomerantz LLP has filed a class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), alleging securities fraud and unlawful business practices. The lawsuit concerns the company's investigational gene therapy for Danon disease, which experienced an unexpected serious adverse event (SAE) leading to a significant decline in stock price.

On May 27, 2025, Rocket Pharmaceuticals announced that a patient participating in the Phase 2 pivotal trial of RP-A501, its investigational gene therapy for Danon disease, experienced an unexpected SAE, resulting in the patient's death. The FDA subsequently placed a clinical hold on the trial to allow for further evaluation [2].

The stock price of Rocket Pharmaceuticals fell by 62.84% on the news, closing at $2.33 per share from a previous high of $9.00 [2]. Investors who purchased or acquired Rocket securities during the class period are advised to contact Danielle Peyton at Pomerantz LLP to inquire about their eligibility to participate in the class action lawsuit [2].

The class action lawsuit alleges that Rocket Pharmaceuticals and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. Investors have until August 11, 2025, to ask the Court to appoint them as Lead Plaintiff [2].

Pomerantz LLP is a leading firm in corporate, securities, and antitrust class litigation, known for recovering numerous multimillion-dollar damages awards on behalf of class members [2].

References:
[1] https://www.globenewswire.com/news-release/2025/07/26/3122105/0/en/RCKT-INVESTOR-ALERT-Rocket-Pharmaceuticals-Inc-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit-RGRD-Law.html
[2] https://www.gurufocus.com/news/2997860/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-inrocketpharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadlines--rckt